TAF6 and pancreatic neoplasm: In the leukemia cell line HL-60 with the NRASQ61L mutation and the pancreatic cancer cell line MIA PaCa-2 with the KRASG12C mutation, the mRNA expression of DOHH, HIST1H2AC, and TAF6 were measured with MEK-I treatments.